Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.
Aiosyn的外部链接
Toernooiveld 300
NL，Gelderland，Nijmegen，6525 EC
?????? ?????? ???????? ?????? ?????? ????????????????Check the breast cancer image in the comments and vote in our poll on how many mitoses you can spot. Follow our page to see next week’s follow-up with the poll results and the AI-powered detection by Aiosyn Mitosis Breast.
此处无法显示此内容
在领英 APP 中访问此内容等
Adopting AI in pathology should not be hindered by cost concerns. At Aiosyn, we offer?pilot opportunities, assistance in building a business case and ROI analysis, and flexible?pricing models to fit your needs. Our AI tools are built to enhance efficiency and precision, covering tasks like quality control of histology images, mitotic figure counting, and kidney image analysis. With a focus on?flexibility?and reliability, we aim to help you streamline your processes and achieve more on your terms. Ready to explore how our solutions can support your work? Let’s start the conversation. https://lnkd.in/g_ZmeWz2 #AIinPathology #DigitalPathology #Automation
???????? ???? ???????????????????????? ?????????? ???????? ?????????? ?????????? ???????????????? ???????????????????? ?????????? ???????????? ??????????????????????? This breast resection analysis showcases how AI can transform clinical diagnosis for pathologists. Evaluating mitotic activity (dividing cells) in breast tissue slides is a tedious and time-consuming task, particularly in labs handling a high volume of breast cancer cases. With Aiosyn Mitosis Breast, our application for mitotic figure counting in breast cancer grading certified under the IVDR, pathologists can review the algorithm's output, ???????????????? ???????????????????? ???????? ???? ???? ???? ????%. Contact us to see how this application improves efficiency, productivity, and consistency in clinical settings. https://lnkd.in/g_ZmeWz2 #AIinPathology #CancerDiagnosis #BreastCancer #DigitalPathology
Thank you, Greg Cima, for your recent interview with our CTO, David Tellez, for 360Dx. It was a pleasure to discuss our journey to achieving CE-IVDR certification for Aiosyn Mitosis Breast and share our vision for the future. At Aiosyn, we are dedicated to enabling AI-powered pathology in existing workflows, improving efficiency and consistency in clinical and preclinical assessments. ?? Interested in learning more about our solution validation and integration? Let’s connect! https://lnkd.in/g_ZmeWz2 Read the full interview: https://lnkd.in/gif_hTTF (Note: Access may be restricted to 360Dx users.) #AIinPathology #CEIVDR #BreastCancer
?? ?????????????????????????? ?????????????? ???? ???????????????????? ?????????? – ???????? ???????????? ??-???????????? Congratulations to everyone involved at Physiogenex, NIPOKA GmbH, and Aiosyn on this recognition! We are proud to see the high interest among the #WCN25 audience in how AI-powered image analysis can support the discovery of new treatments for kidney diseases.? #AIinPathology #Nephrology #PreclinicalResearch #DrugDiscovery
Physiogenex, NIPOKA GmbH and Aiosyn awarded at the World Congress of Nephrology 2025 in New Delhi! I was so happy for the opportunity to present the great work on IgA nephropathy performed by my colleagues at Physiogenex and our expert partners in image analysis, NIPOKA GmbH and Aiosyn at #WCN25. But during the Saturday poster session, my happiness raised exponentially when I received the International Society of Nephrology Award for the most viewed e-poster during the whole congress ! This is what may happen when you work with experts who deliver their best in running preclinical drug efficacy studies and imaging analysis, with a common objective: new effective therapies for our patients. Congratulations to you all for this fantastic achievement, with a special “bravo” to Dr Estelle Grasset, PhD who setup our IgA nephropathy rat model with the Physiogenex team! P.S.: I made a stop on the way to the conference at the wonderful Shiv Murti Delhi (Hindu temple) where the mouse/rat of Ganesh is represented - see the picture: I may be biased by the award, but am I right to say it is a rat ??? If you wish to discuss your next preclinical study with Physiogenex, contact us: www.physiogenex.com We have a 20-year expertise in preclinical drug development and a 97.5% customer satisfaction rate over the last 4 years. Our expertise??Your success Estelle Grasset, PhD Prof. Dr. Nicole Endlich Vedran Dreni? B?a?ej Dolicki Thomas de Bel Thierry Sulpice Patrick de Boer Claire Bigot, PhD, PharmD Anna Correas Grifoll Victoria Grosu #nephropathy #IgANephropathy #preclinicalresearch #drugdiscovery #ThisisISN #nephrology #theworldcongressofnephrology
?? Our first newsletter of 2025 is here! We have exciting updates this year, including a new feature for AiosynQC, a case study, the first IVDR-certified algorithm for mitosis counting, a new collaboration, and more. Check the full issue below!
We are thrilled to announce that AiosynQC, our AI-powered quality control solution, has been updated to detect issues related to white balance settings in digital histology slides. This improvement assists laboratory technicians in identifying these problems more efficiently, helping streamline the diagnostic and research pathology workflow. Read the full announcement: https://lnkd.in/dvmiPE9i #AIinPathology #DigitalPathology #QualityControl
Aiosyn is proud to have contributed to Physiogenex’s study validating a novel rat model of IgA nephropathy and confirming the efficacy of atrasentan on glomerulonephritis.? Our NephroPath AI analysis confirmed that atrasentan reduces mesangial expansion. ?? ?? Join the poster presentation (SAT-115) at #ISNWCN on Feb 8, 2025, in New Delhi! Congratulations Estelle Grasset, PhD and Physiogenex team! We are excited to push the boundaries of preclinical research and accelerate drug discovery together. #IgANephropathy #PreclinicalResearch #DrugDiscovery
I am pleased to inform you that Physiogenex will be presenting the effects of atrasentan (a selective endothelin type A receptor antagonist), in its novel rat model of IgA Nephropathy at the #ISNWCN conference in New Delhi next week! Do not miss our poster presentation (number SAT-115) on Saturday, February 8, 2025, 17:30-18:30 Or check the abstract here https://lnkd.in/e6wrH4Bc Importantly, this new study has been conducted with our wonderful partners NIPOKA GmbH and Aiosyn, 2 world-class companies with unique expertise in imaging analysis, to confirm the validity of our preclinical model and the efficacy of atrasentan: ?? NIPOKA GmbH Podocyte Exact Morphology Measurement Procedure (PEMP) demonstrated that atrasentan reduced the effacement of podocytes ?? Aiosyn innovative Kidney AI suite demonstrated that atrasentan reduced mesangial expansion A big bravo and merci to Dr. Estelle Grasset, PhD Grasset and her team at Physiogenex, and to our great collaborators on this new preclinical model validation. We hope this model and the imaging technology delivered by our partners will help developing new therapies to patients suffering IgA Nephropathy. ? If you wish to discuss your next preclinical study, please contact us: www.physiogenex.com We have a >20-year expertise in preclinical drug development and 97.5% customer satisfaction over the last 4 years. Our expertise ?? Your success ? Estelle Grasset, PhD Prof. Dr. Nicole Endlich Vedran Dreni? B?a?ej Dolicki Thomas de Bel Thierry Sulpice Patrick de Boer Claire Bigot, PhD, PharmD Anna Correas Grifoll Victoria Grosu #nephropathy #IgANephropathy #preclinicalresearch #drugdiscovery
?? ???????????????? ????????! NephroPath’s AI-powered kidney tissue analysis tools are now integrated into HistoWiz’s PathologyMap? platform! This collaboration brings state-of-the-art AI solutions to researchers, enabling ????????, ??????????????, ?????? ???????????????????????? renal tissue analysis for (pre)clinical studies. With Aiosyn’s algorithms, PathologyMap? users can perform ??????-?????????? ????????????????????????????, streamlining workflows and enhancing insights into kidney disease progression and treatment efficacy. By improving the identification of pathological changes, this integration supports breakthrough discoveries in renal research. ?? ???????? ?????? ???????? ?????????? ????????: https://lnkd.in/dBgrgN_3 #AIinPathology #KidneyResearch #BiomarkerDiscovery #DrugDevelopment
Thank you, Oost NL, for showcasing our mission and celebrating our recent CE IVDR certification! These healthcare advancements would not be possible without the support of our partners. Together, we are shaping the future of precision pathology to improve patient care. ??? Watch the video to learn more about our mission! Note: The video is in Dutch. An English-subtitled version will be available in the coming weeks—stay tuned ??
Onlangs behaalde Aiosyn uit Nijmegen de CE-markering voor hun AI-oplossing voor borstkankerdiagnose. Een belangrijke stap, want borstkanker is wereldwijd de meest voorkomende vorm van kanker bij vrouwen, met 2,3 miljoen nieuwe gevallen per jaar. Aiosyn ontwikkelt een diagnostisch platform dat met AI pathologen ondersteunt voor nauwkeurigere en effici?ntere klinische diagnostiek. De CE-markering bevestigt de kwaliteit en veiligheid van hun technologie – een belangrijke mijlpaal voor de spinoff van Radboudumc ?? Oost NL is samen met LUMO Labs, Health Innovations en Radboudumc holding investeerder in Aiosyn. Bekijk deze video om te zien hoe zij met een slimme oplossing over- en onderbehandeling kan voorkomen, en zo bijdraagt aan het betaalbaar houden van de zorg. ? Jeroen van der Laak | Patrick de Boer | Wouter Bulten | Bj?rn Schaap | Thomas Hensel ?? Video geproduceerd door Ger de Gram